Suretone Pictures and SRM Announce Media Agreement, Jordan Schur Joins Company as Advisor

The Future of Entertainment: SRM Entertainment and Suretone Pictures Alliance Exciting News in the Entertainment Industry JUPITER, FL, Sept. 24, 2024 (GLOBE NEWSWIRE) — SRM Entertainment, Inc. , (Nasdaq: SRM) (the “Company” or “SRM”) SRM and Suretone Entertainment’s Suretone Pictures are in negotiations to form an alliance capitalizing on Suretone Pictures’ film productions, tv content…

Read More

Breaking News: Enlivex Gets Thumbs Up to Move Forward with Phase II Trial for Knee Osteoarthritis Treatment!

Exciting News from Enlivex Therapeutics Ltd. September 24, 2024 An Update on Phase I/II Clinical Trial of Allocetra™ Hey there! Did you hear the latest news from Enlivex Therapeutics Ltd.? Well, if you haven’t, let me fill you in on the exciting developments in their Phase I/II clinical trial of Allocetra™ for patients with knee…

Read More

Anfield Launches Exciting Drill Program at Slick Rock: Uncovering the Potential of a Promising Site

Welcome to the Future of Energy Exploration Anfield Energy Inc. Launches Rotary Drill Program VANCOUVER, British Columbia, Sept. 24, 2024 (GLOBE NEWSWIRE) — Anfield Energy Inc. (TSX.V: AEC; OTCQB: ANLDF; FRANKFURT: 0AD) (“Anfield” or “the Company”) is pleased to announce that it has commenced a 20-hole, 20,000-foot rotary drill program at its Slick Rock uranium…

Read More

FDA Accepts Arcutis’ Supplemental New Drug Application for ZORYVE Roflumilast Foam for Scalp and Body Psoriasis Treatment

Arcutis Biotherapeutics Announces FDA Acceptance of sNDA for ZORYVE Foam Introduction The U.S. Food and Drug Administration (FDA) has set a Prescription Drug User Fee Act (PDUFA) target action date of May 22, 2025 for Arcutis Biotherapeutics’ supplemental New Drug Application (sNDA) for ZORYVE (roflumilast) foam 0.3%. This next-generation phosphodiesterase-4 (PDE4) inhibitor is aimed at…

Read More

Spectral AI Hits Milestone: 25 Patients Enrolled in U.S. Burn Study at Emergency Departments, Expands Clinical Trial Sites

Spectral AI, Inc. Achieves Significant Milestone in Burn Pivotal Study Introduction In a recent press release, Spectral AI, Inc. announced that it has reached a major milestone in its U.S. Burn Pivotal Study. The company, known for its focus on leveraging artificial intelligence for medical diagnostics in wound care, has successfully enrolled 25% of the…

Read More

Unlocking the Power of Access: A Comprehensive Guide to Navigating the World of Online Articles

New Data on Opioid Use Disorder Program at Society for Neuroscience Meeting Ensysce CEO Invited Expert Speaker at Formulation & Delivery US 2024 Meeting SAN DIEGO, CA / ACCESSWIRE / September 24, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) (“Ensysce” or the “Company”), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing…

Read More

Director of PayPoint plc Discloses Personal Shareholding: A Significant Update for Investors

PayPoint plc Share Incentive Plan Transactions Notifications of transactions by PDMRs 23 September 2024 PayPoint plc has released details regarding the monthly acquisition of Partnership Shares and award of Matching Shares under the PayPoint plc Share Incentive Plan (SIP) on 23 September 2024. This includes transactions made by Persons Discharging Managerial Responsibilities (PDMRs), which includes…

Read More